| Literature DB >> 31029152 |
Xubin Qiu1, Ming Zhuang1, Ziwen Lu2, Zhiwei Liu1, Dong Cheng1, Chenlei Zhu1, Jinbo Liu3.
Abstract
BACKGROUND: Low back pain has become a serious social and economic burden and the leading cause of disability worldwide. Among a variety of pathophysiological triggers, intervertebral disc (IVD) degeneration plays a primary underlying role in causing such pain. Specifically, multiple independent endplate changes have been implicated in the initiation and progression of IVD degeneration.Entities:
Keywords: Apoptosis; Degeneration; Intervertebral disc; RIPK1
Year: 2019 PMID: 31029152 PMCID: PMC6487042 DOI: 10.1186/s12967-019-1886-3
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Fig. 1Signaling network of pathology-associated proteins in intervertebral disc degeneration diseases. Reported pathology-associated proteins in intervertebral disc diseases were used as signaling nodes and input into the meta-search engine of protein–protein interaction database String. Interactions from experiment, database, neighborhood, gene fusion, co-expression, and co-occurrence were included in the search. The confidence score of 0.15 was used and only direct protein–protein interactions were counted. We included 70 genes with highest confidence and interaction scores in the signaling network for later experiments. Cyan, pink, green, blue, and black lines indicate known interactions from curated databases, experiments determined, gene neighborhood, gene co-occurrence, and co-expression, respectively. Gene names of these proteins were used in the figure
Fig. 2Potential intervertebral disc degeneration-associated proteins identified using patient specimens. a Representative NMR images of patients’ spines with Modic grades before the surgery. b Representative NMR images of patients’ spines after the surgery. c Representative specimen images of normal and degenerative endplates from the patient surgery. d Relative mRNA expression of patients’ degenerative versus normal endplates (Patient 1–Patient 7) detected through qRT-PCR experiments with 70 genes of IVD degeneration-associated proteins in the signaling network. Color scale is shown in the corresponding figure
Patients’ characteristics
| No | Age | Sex | Body mass (kg/m2) | Diabetes mellitus | Herniation type | Disc degeneration grade (Pfriimann) | Endplate changes (Modic) | Disc height (mm) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive | Negative | Protrusion | Sequestration | Extrusion | (I–IV) | (0–3) | |||||
| P1 | 49 | M | 22.84 | √ | √ | III | 2 | 14.7 | |||
| P2 | 76 | F | 23.44 | √ | √ | IV | 2 | 14.4 | |||
| P3 | 60 | M | 22.57 | √ | √ | √ | IV | 2 | 5.7 | ||
| P4 | 72 | M | 23.56 | √ | √ | III | 1 | 11.1 | |||
| P5 | 63 | M | 27.12 | √ | √ | II | 1 | 15.1 | |||
| P6 | 62 | M | 25.61 | √ | √ | II | 1 | 10.0 | |||
| P7 | 46 | M | 23.12 | √ | √ | II | 1 | 14.9 | |||
Potential intervertebral disc degeneration-associated proteins
| Gene name | Official full name | Relevance to IVD disease | References |
|---|---|---|---|
| BCL2 | BCL2, apoptosis regulator | NP apoptosis, IVD degeneration | [ |
| BMP1 | Bone morphogenetic protein 1 | OA, osteoblast, osteoclast activities | [ |
| EGFR | Epidermal growth factor receptor | IVD degeneration, OA, joint disease/arthritic joints, meniscal injury, post-traumatic OA, articular cartilage, rheumatoid arthritis (RA) | [ |
| ERBB2 | Erb-b2 receptor tyrosine kinase 2 | IVD degeneration, arthritis, RA | [ |
| ESR1 | Estrogen receptor 1 | Osteoporosis, OA, IVD degeneration | [ |
| FGF2 | Fibroblast growth factor 2 | IVD degeneration, disc/bone regeneration, OA | [ |
| IGF1 | Insulin like growth factor 1 | IVD, OA, bone formation and growth, bone mineral density | [ |
| LCK | LCK proto-oncogene, Src family tyrosine kinase | RA | [ |
| MMP1 | Matrix metallopeptidase 1 | Arthritis, IVD, OA, articular cartilage | [ |
| MMP13 | Matrix metallopeptidase 13 | Arthritis, OA, IVD degeneration, OA, chondrocytes | [ |
| MMP2 | Matrix metallopeptidase 2 | IVD, bone mineralization, joint erosion and defects, OA, RA | [ |
| MMP3 | Matrix metallopeptidase 3 | Cervical spondylosis, IVD degeneration, OA | [ |
| MMP7 | Matrix metallopeptidase 7 | Arthritis, IVD, OA | [ |
| MMP9 | Matrix metallopeptidase 9 | Arthritis, IVD, RA, OA | [ |
| NFKB1 | Nuclear factor NF-kappa-B p105 subunit | OA, IVD degeneration, cervical spondylosis, bone development, osteoporosis | [ |
| NGF | Nerve growth factor | IVD, OA, bone injury | [ |
| PDPK1 | 3-Phosphoinositide dependent protein kinase 1 | None | |
| PPP5C | Protein phosphatase 5 catalytic subunit | None | |
| PTGR1 | Prostaglandin reductase 1 | None | |
| RIPK1 | Receptor interacting serine/threonine kinase 1 | IVD, arthritis, bone marrow necroptosis | [ |
| SRC | Proto-oncogene tyrosine-protein kinase Src | Chondrocytes, bone marrow, osteoclast, OA | [ |
| STAT3 | Signal transducer and activator of transcription 3 | Bone defect healing, OA, IVD, articular chondrocytes | [ |
| TGFB1 | Transforming growth factor beta 1 | OA | [ |
| TGFBR1 | Transforming growth factor beta receptor 1 | OA, articular cartilage | [ |
| UBC | Ubiquitin C | IVD, bone destruction and pathologic fracture | [ |
| WASL | Wiskott–Aldrich syndrome like | Bone loss or osteoporosis | [ |
Fig. 3Short-term RIPK1 knockdown led to inflammation in primary chondrocyte cells. a Construction of shRIPK1 vectors. b mRNA levels of RIPK1 5 days after shRIPK1 knockdown detected by qRT-PCR. c Representative Western blot results of shRIPK1 knockdown after 5 days. d Inflammatory cytokines levels 5 days after shRIPK1 knockdown. Data indicate the mean values calculated from triplicate samples from multiple independent experiments (n ≥ 3) (± SD). Differences were between shRIPK1 groups and the shControl group. *P < 0.05; **P < 0.01; ***P < 0.001
Fig. 4Long-term RIPK1 knockdown led to apoptosis in primary chondrocyte cells. a Representative pictures of SA-β-gal staining at 15 days after shRIPK1 knockdown. b Statistical analysis of A and of SA-β-gal positive cells in IL-1β induced senescence with or without overexpression of RIPK1. c Representative flow cytometry plots for primary chondrocyte cells with RIPK1 knockdown for 15 days. Cells were stained with Annexin V-FITC/propidium iodide and analyzed for cell apoptosis distribution. d Statistical analysis of C for the presence of Annexin V (+)/PI (−) (early apoptosis) and Annexin V (+)/PI (+) (late apoptosis)
Fig. 5Long-term RIPK1 knockdown triggered apoptosis through the cleaved caspase 3 pathway, while downregulating NF-κB and MAPKs cascades in primary chondrocyte cells. a mRNA levels of TNF 15 days after shRIPK1 knockdown detected by qRT-PCR. b mRNA levels of TNFAIP3, CCL2, and IκBα 15 days after shRIPK1 knockdown and at the indicated time after TNF stimulation, detected by qRT-PCR. c Detection of p-IKKα/β, p-JNK, p-p38, and cleaved caspase 3 in the protein lysates using western blotting. Data indicate the mean values calculated from triplicate samples from multiple independent experiments (n ≥ 3) (± SD). *P < 0.05; **P < 0.01
Fig. 6Apoptosis induced in animal models of caudal vertebra intervertebral disc degeneration through TNF-induced caspase-dependent RIPK1 pathway. a H&E staining of endplates of animal models of caudal vertebra intervertebral disc degeneration and control group at the indicated time. b mRNA levels of TNF, RIPK1, JNK, and IKKα in primary chondrocyte cells from endplates of animal models as indicated. c Apoptotic cells of primary chondrocyte cells from endplates of animal models treated as indicated and detected by flow cytometry. Data indicate the mean values calculated from triplicate samples from multiple independent experiments (n ≥ 3) (± SD). *P < 0.05; **P < 0.01